Leflunomide in the treatment of lupus nephritis study.docVIP

 PAGE \* MERGEFORMAT 3 Leflunomide in the treatment of lupus nephritis study [Paper Keywords]: Leflunomide in lupus nephritis [Abstract]: Objective: To study the leflunomide treatment of type Ⅳ lupus nephritis clinical effects, safety and side effects. Methods 46 patients with lupus nephritis (LN) patients, renal biopsy showed lupus nephritis for the application of leflunomide combined treatment with corticosteroid for 6 months, medication during the monitoring of blood routine, urine routine, 24h urinary protein, liver renal function, anti-nuclear antibody and anti-double-stranded antibody titers, erythrocyte sedimentation rate, and complement C3 and so on, six month later, the efficacy and safety evaluation. Results: Leflunomide therapy LN remission rate of urinary protein was 72.4%, higher than cyclophosphamide pulse therapy remission rate 57%, LN activity indicators to ease rates than the latter. Conclusion: Leflunomide combined glucocorticoid therapy can effectively control lupus activity and side effects are mild and well tolerated. Clinical efficacy of systemic lupus erythematosus is an involving multi-system, multi-organ autoimmune disease, whose main clinical manifestations of inter rash, there are kidney, liver, heart and other organ damage, and often accompanied by fever, joint pain and other carboxylic systemic symptoms, systemic lupus erythematosus who had renal damage, namely, lupus nephritis (LN), the incidence of lupus nephritis Gejia reported mixed results in the diagnosis of SLE, about 70% had significant renal damage, if the SLE patient’s renal biopsy, light microscopy, the renal impairment up to 90%, leflunomide is a synthetic isoxazole class of drugs is available through pyrimidine synthesis, so that B lymphocytes and T lymphocyte proliferation stopped in the G1 phase, inhibit antibody and lymphokine synthesis and secretion, and thus inhibit lymphocyte-mediated cellular and humoral immune response. 1 Materials and Methods 1.